The current guidelines of immunotherapeutic treatment base eligibility of patients for PD-1/PD-L1 inhibitors mainly on PD-L1 levels on the primary tumour or, as of recently, on tumour-mutation burden (TMB) levels [24,25,26]. Here, CD274 is linked to neoplasm.